Objectives: This study aimed to examine changes to the microbiota composition and metabolic profiles of seven patients with recurrent Clostridium difficile infection (rCDI), following treatment with faecal microbiota transplant (FMT).
Introduction
Although Clostridium difficile is present in the intestines of ~3-5% of healthy adults, 1 the occurrence of C. difficile infection (CDI) in healthy individuals is relatively uncommon due to the protective effect of the gut microbiota. The incidents and severity of CDI has risen significantly over the last decade, and it is now recognised as the main causative agent of healthcare-associated infectious diarrhoea in hospitals worldwide. 2 The standard treatment for CDI is the administration of metronidazole for mild to moderate infections, and oral vancomycin or fidaxomicin for severe infections and relapses. The ability of C. difficile to form spores, coupled with the increase in antibiotic-resistant strains, can lead to persistence of infection, relapses, and the administration of more antibiotics, which further depletes the commensal bacteria. This creates an environment that is more favourable to C.
difficile, thus setting up a cycle of relapse and re-infection. It is estimated that 20-30% of patients who develop a first episode of CDI go on to have at least one relapse, and of these, a further 60% develop further episodes of relapses. 3 This increases the need for further antibiotics, the risk of antibiotic-resistance in the gut commensal flora, and costs to the health service, with each episode of CDI estimated to cost approximately £7000 in 2010. 4 Faecal microbiota transplants (FMT) represents an effective alternative to antibiotics to treat recurrent CDI (rCDI), with a primary cure rate as high as 91%. 5 The central tenet behind FMT is that the introduction of a healthy bacterial community into the intestines produces an environment that is less favourable to C. difficile by increasing colonisation resistance and reinstating a protective effect. The
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advantages of this treatment are that it is quick, cost-effective, and could help to eradicate antibiotic resistant strains of C. difficile.
It is known that a dysbiotic gut microbiota increases the risk of developing CDI, however whether there is a common element within this community composition that could help to determine if a patient is at greater risk of rCDI is as yet unknown. The reduction in diversity within the dysbiotic gut microbiota would also suggest a reduction in metabolic potential through the loss of gene diversity. The functional redundancy 6 within the gut microbiota suggests, that metabolic function is more relevant than which species are present or absent. Whilst a number of studies have looked at the changes in microbiota composition due to FMT, [7] [8] [9] [10] we know little about the changes to the metabolic capacities of the altered microbiota. The aim of this study was to assess FMT-induced changes in both the microbial community structure and metabolite profiles of the gut microbiomes of seven patients with rCDI, as well as those of their associated FMT donors.
Patients and methods

Patients
Patients were selected as candidates for the FMT procedure if they had at least two confirmed recurrences of CDI. C. difficile testing was based on a two stage algorithm in line with Public Health England recommendations. 11 This involves screening faecal samples by glutamate dehydrogenase enzyme immunoassay (Techlab, USA), followed by C. difficile toxin testing by enzyme immunoassay (Techlab, USA).
Glutamate dehydrogenase positive, toxin negative samples were further tested for the presence of toxigenic genes by PCR. FMT exclusion criteria included immunocompromised patients, those aged less than 16, and those with severe
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comorbidities which would make the patient unfit for endoscopy. FMT was introduced into clinical care at Norfolk and Norwich University Hospital following approval by the New Therapies committee, and was performed in accordance with the Helsinki Declaration of 1975. Patients were consented for the study by a clinician following a detailed discussion of the procedure with the patient or their next of kin.
All patient data is fully anonymised.
Donor screening
The faecal donors used for the cohort of patients who underwent FMT in this study 
shellfish, and to complete a short screening questionnaire to confirm no changes to health or lifestyle since the last donor screening that may put the patient at risk.
Faecal suspension preparation
Donor faeces were collected in a sterile container on the day of the procedure, and transferred to a sterilised class II safety cabinet (Walker Ltd, UK). A maximum of 80 g of donor stool was homogenised with sterile saline (0.9%), to a ratio of 5 ml saline per gram of stool, in a strainer bag (BA6141/STR; Seward Limited, UK) using a Stomacher® 400 Circulator (Seward Limited, UK) set to 230 RPM for a duration of 1 minute. The filtered faecal preparation was drawn up into labelled sterile 60 ml syringes using nasojejunal tubing connected to the Luer lock. The syringes were secured with sterile Luer lock caps and transported immediately to the hospital.
Aliquots of the donor faecal sample were immediately stored at -20 ˚C until analysis.
Faecal suspension infusion
Patients were prescribed oral vancomycin 500 mg four times daily for 4 days, with the last dose received the night before the procedure. Also, on the day before the FMT procedure, a bowel lavage is performed using 4 litres of macrogol solution (Klean-Prep, Norgine). Patients were taken to the endoscopy unit for insertion of nasojejunal tube the night before the procedure. Our FMT protocol was adapted from that of van Nood et al. 12 On the day of FMT infusion, the patient"s headrest was elevated to 45 degrees, patency of the nasojejunal tube was checked by flushing with water, and 420 ml of faecal suspension was delivered slowly by the patient"s bedside in the isolation room via a nasojejunal tube using the prefilled syringes. This was performed at a rate of ~20 ml per minute with a break of 5-10 minutes applied
halfway through the procedure. Post-infusion instructions were to monitor observations, and record bowel motions. Patients could take on fluids one hour after the procedure, and were observed overnight before discharge the next day at the earliest. Although there are no agreed durations of follow-up post-FMT, 13 van Nood et al 12 used two endpoints to measure cure, namely no relapse after 5 weeks, and no relapse after 10 weeks. Resolution was defined as type 4 or less on the Bristol stool chart or stool normal for the patient e.g. in case of percutaneous endoscopic gastrostomy feeding. We followed patients up by telephone or in person if they were re-admitted into the hospital for an unrelated illness. Post-FMT samples were collected after a minimum of 10 days post-FMT, and postal kits were provided to patients who were willing to donate a "follow-up" sample up to 2 weeks later.
Sample analysis
Faecal microbiota analysis
Faecal samples were collected from recipients within 9 days prior to FMT, however the pre-FMT sample for patient R13 was not collected within this timeframe, and a previously frozen sample obtained whilst the patient was suffering from the same episode of CDI was used. Further samples were collected for all recipients following the procedure ("post-FMT" range: 11-141 days; "follow-up" range: 4-14 days after post-FMT sample), and stored at -20 ˚C until analysis. The DNA was extracted using the FastDNA SPIN Kit for Soil (MP Biomedicals, UK) with a bead-beating step.
14 DNA yield was quantified using the Qubit fluorometer prior to the samples being sent to the Earlham Institute (UK), where the V4 hypervariable region of the 16S rRNA genes were amplified using the 515F and 806R primers with built-in degeneracy. 15 The amplicons were sequenced using paired-end Illumina sequencing (2 x 250 bp)
on the MiSeq platform (Illumina, USA). Sequencing data, for the 21 samples that had an appropriate level of sequencing depth, were analysed using the Quantitative Insights Into Microbial Ecology (QIIME) 1.9 software and RDP classifier 16S rRNA gene sequence database. 16, 17 The trimmed reads were filtered for chimeric sequences using ChimeraSlayer, bacterial taxonomy assignment with a confidence value threshold of 50% was performed with the RDP classifier (version 2.10), and trimmed reads clustered into operational taxonomic units at 97% identity level. Alpha diversity and rarefaction plots were computed using the Chao1 index. Weighted and unweighted UniFrac distances were used to generate beta diversity principal coordinates analysis plots, which were visualised using the Emperor tool.
Faecal metabolite analysis
A known mass (~ 100 mg) of thawed faecal samples were added to sterile tubes. 
Statistical analysis
Data for groups were expressed as mean ± standard deviation, with the exception of the microbiome relative abundance data, which is expressed as median ± standard deviation. Statistical comparisons of the alpha diversity measurements were performed using one-way analysis of variance followed by Tukey"s Multiple (The MathWorks Inc., Natick, MA). Prior to CCA and calculation of the correlation coefficient, the sequencing data were subjected to the centered log-ratio transformation to avoid spurious results.
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Results
Patient demographics
Seven patients with rCDI were given FMT at the Norfolk and Norwich University
Hospital. Metagenomic and metabonomic analyses were performed on stool samples collected before and after the FMT procedure, along with the associated donor stool samples. Patient demographics are shown in Table 1 .
16S rRNA gene sequencing analysis
Faecal microbiota composition
The sequencing data generated 1,627,111 high-quality reads, with an average of 77,481 ± 10,888 reads per sample, which clustered into 9,818 operational taxonomic The results in Table 2 
Faecal microbiota diversity analyses
Alpha diversity analysis using the Chao1 index ( Figure 3 ), and one-way ANOVA with
Tukey"s multiple comparisons test, indicated a significant reduction in bacterial diversity in the pre-FMT samples, compared to the donor samples (P = 0.0091).
Although bacterial diversity was observed to increase following the FMT procedure, this was not statistically significantly different to the diversity within the pre-FMT samples. However, neither the post-FMT nor the follow-up samples were
significantly different from the donor samples, indicating an increase in bacterial diversity following FMT. Weighted beta diversity analysis indicated a clear separation between samples obtained from donors, which clustered to the right of the principle coordinates analysis plot, and those from recipients prior to FMT, which were located on the left side of the plot (Figure 4 ). In addition, it indicates that the faecal microbiota of R42, R05, and R23 were modified by the FMT procedure to closely resemble that of the healthy donors.
Faecal metabolite profile
A total of 22 samples obtained from 2 donors (n = 5) and 7 patients (pre-FMT n = 7, post-FMT n = 7, and follow-up samples n = 3) were prepared, figure 3) .
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As with the donor"s profiles, the patient profiles displayed great intra-and interindividual variability in the levels of many metabolites. mmol/kg), and although there was a decrease in putrescine levels, the amount of cadaverine and tyramine were largely unchanged. Interestingly, increased levels of lactate, 1,2-propanediol, glycerol, and glucose were observed in this patient following was detected compared to pre-FMT levels ( Figure 5 ). The levels of butyrate, acetate, and fucose increased post-FMT converging towards those of the donors (Supplemental figure 4) . Despite this improvement, the levels of butyrate, acetate, ethanol, methanol, galactose, arabinose, deoxycholate, lithocholate, and isovalerate remained significantly different compared to the donor samples, even after the FMT procedure (Table 3 ). Only the levels of galactose and arabinose significantly differed from the donors in the follow-up samples (Table 3) . Principal component analysis indicated that a positive score on the second principal component (PC) may potentially correlate with a healthier metabolic profile, as the scores of all five of the donor samples were found in this half of the score plot (Supplemental figure 5) .
Interestingly, some of the patients" metabolic profiles (R44, R42, and R23) shifted towards the profiles of the donors to varying degrees after the FMT procedure.
Correlation analysis
The figure 7) . Two clusters of variables can be seen on the first axis, one with large negative, and the other with large positive coordinates. These two sets of variables are expected to be negatively correlated. Moreover, it is expected that variables within a cluster will be positively correlated. 19 Further examination of the map of Pearson correlations between these two clusters of variables confirms the high correlations between a number of metabolites and bacterial taxa ( Figure 6 ).
For instance, butyrate was found to positively correlate to the presence of Bacteroides, Blautia, and Ruminococcus, whilst Klebsiella and Enterococcus were negatively correlated with butyrate.
Discussion
In this study, we performed gut microbiota community composition and metabonomic analyses on the faecal samples of seven patients who underwent FMT to combat r-CDI. The symptoms associated with CDI were resolved for six of the seven patients, and no recurrences of CDI have been reported in the 22 -27 months following the single administrations of FMT. It has been observed that CDI sufferers generally have a dysbiotic microbiota, with a larger proportion of Proteobacteria than is generally seen in a healthy microbiota. 7, 26 Our results based on the 16S rRNA gene analysis confirm the higher levels of Proteobacteria in rCDI patient samples before FMT. Post treatment there was a general increase in the relative proportions of
Firmicutes and Bacteroidetes, with a decrease in members of the Proteobacteria as has been previously described. 7, 26 At a higher resolution, the relative proportions of Bacteroides, Blautia, and Ruminococcus from the Lachnospiraceae family increased,
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whilst Enterococcus and the Proteobacteria Escherichia and Klebsiella decreased, which supports the findings of previous studies. 8-10, 26, 27 Interestingly these changes were not observed in patient R44, whose post-FMT sample, collected 11 days after the procedure, continued to resemble a dysbiotic community, and on the contrary, the levels of Klebsiella (Proteobacteria) increased from 5.8% to 84.6% (Supplemental figure 2) of the total bacterial population. Despite what appears to be an adverse effect on the gut microbiota composition, rCDI was resolved, and it is possible that the patient microbiota had changed after FMT but over the eleven days before a post-FMT sample was collected, a resumption of alcohol abuse had reversed this effect. It is known that chronic alcohol use can lead to a dysbiotic microbiota, with a predomination of Gammaproteobacteria including Klebsiella species, as was observed with patient R44. [28] [29] [30] Therefore, the long-term success of FMT procedures may be influenced by lifestyle, and it could be interesting to explore if chronic alcohol abuse increases the susceptibility of individuals to CDI.
As with some other gastrointestinal diseases, a reduction in the diversity of the colonic microbiota is commonly seen in CDI patients. 31, 32 Alpha diversity measurements ( Figure 3 ) indicated that the donor"s gut microbiota contained a higher species richness than the patients before FMT (P = 0.0091). The administration of FMT increased the diversity of patients" gut microbiota, and this remained stable over time, although this diversity did not reach the levels observed in the healthy donors. This is potentially due to the natural decline in bacterial diversity that has been reported in the gut microbiota as we age (mean age: FMT recipients 71.3 ± 15.9 years; donors 33.0 ± 4.2 years). 33, 34 Beta diversity analysis (Figure 4) , which gives an indication of the similarities or differences between samples, shows a clear separation of the donor"s and pre-FMT patient samples,
indicating substantial differences between the microbiota profiles of the two groups.
As this separation was determined by principal coordinate 1, it suggests that the microbiota composition of the two groups represented the greatest variability. After treatment, the profiles shift towards the associated donor samples.
Metabonomic analysis was performed using 43 and inflammatory responses. 44 Using sparse partialleast-square (sPLS) canonical correlation analysis, it was possible to separate donor and patient samples based on microbiota composition and metabolite profile (Supplemental figure 6) . Furthermore, calculating the Pearson correlation coefficient enabled correlations between bacterial taxa and metabolites to be mapped (Figure
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. This identified a range of metabolites, including butyrate, which were positively correlated with the taxa (Bacteroides, Blautia, and Ruminococcus) that proportionally increased following FMT, and negatively correlated with Klebsiella (except for a largely neutral correlation to succinate), and Enterococcus, which exhibited proportional decreases. Many of the rCDI patients had relatively high levels of branched chain fatty acids (BCFAs), phenolic compounds, amino acids, and certain amines, compared to the donor samples. In general, the levels of some of these metabolites were found to decrease following the FMT procedure, and this may have also contributed to the improved health of the patients. Although the majority of FMT recipients showed an increase in short-chain fatty acids after treatment, this was not observed in patient R44, who suffered from alcoholism. The increased levels of lactate and glycerol could be an effect of alcohol abuse following ethanol metabolism. 45 It has been shown that Klebsiella can metabolise glycerol under anaerobic conditions to produce propanediols, which can then be used as an energy source for these bacteria. 46 As such, the chronic consumption of alcohol could lead to a dysregulation of hepatic processes, which may provide increased levels of these metabolites that would give bacteria, such as Klebsiella species, a competitive advantage over more beneficial bacteria.
It has previously been shown that chronic alcohol abusers often have increased proportions of Gammaproteobacteria in their gut microbiota, 29 which is consistent with the observations made here. However, further work is required to identify if elevated levels of faecal lactate, glycerol, and propanediols are potential biomarkers of this disorder.
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The results of this study confirm the value of FMT as a viable alternative to the use of costly antibiotics for the treatment of rCDI. Although the modulation of the microbiota composition is considered to play a pivotal role in FMT, the resulting metabolic alteration of the gut microbiota should also be considered as an important factor in the resolution of rCDI. A larger study is in progress focusing on the microbial-based metabolites to identify biomarkers for identification of individuals susceptible to CDI based on both microbiota composition and their metabolic profiles.
Conclusions
Faecal microbiota transplantation has been shown to be a robust and cost-effective method to combat recurrent-Clostridium difficile infection (rCDI), however to increase the effectiveness of this treatment it is necessary to elucidate the mechanisms by which this works, and factors that may reduce its efficacy. Our results indicate that the resolution of rCDI was accompanied by an alteration to the microbiota composition towards that of the donor profile to varying degrees, with increased diversity that was maintained beyond seven weeks after the FMT procedure. We also demonstrated that the shift in bacterial composition also correlated with altered functional metabolism of the recipient microbiota, where the metabolic profile again shifted towards that of the donor. Correlation analysis enabled the identification of strong relationships between bacterial taxa and metabolites, including positive correlations between butyrate and taxa that proportionally increased after FMT.
Finally, lifestyle factors, such as chronic alcohol consumption, could potentially
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increase a person"s susceptibility to CDI, and should be considered prior to FMT administration. 
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A N U S C R I P T M A N U S C R I P T Figure 3 . FMT treatment increased bacterial diversity. Alpha diversity rarefaction measures of faecal bacteria before (n = 7) and after FMT treatment (n = 6), follow-up samples (n = 3), and associated donor samples (n = 5) were calculated using QIIME 1.9.0. Data for the post-FMT sample for patient R48 was omitted due to poor sequencing depth. Mean ± SD, analysed using one-way ANOVA with Tukey"s multiple comparisons test, and an alpha value of 0.05; ** P = 0.0091.
A N U S C R I P T follow-up samples (n = 3)) and donors (n = 5). Beta diversity analysis was performed using the UniFrac metric using QIIME 1.9.0, and visualised as a 3D principal coordinates analysis plot using Emperor. Data for the post-FMT sample for patient R48 was omitted due to poor sequencing depth. The anonymised identifiers indicate which samples belong to each patient, and which donor samples were used for each patient.
A N U S C R I P T A C C E P T E D M A N U S C R I P T Table 2 . Median (± SD) relative abundance of bacterial taxa in which the largest proportional changes were observed across the different groups. The index in ppm indicates the chemical shifts of the most characteristic group of proton(s) for each metabolite. Mann-Whitney t-tests between two groups of samples (donors vs each of the other groups) * P < 0.05, ** P < 0.01
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